SML2903
KIRA8
≥98% (HPLC)
Synonym(s):
(S)-2-Chloro-N-(6-methyl-5-((3-(2-(piperidin-3-ylamino)pyrimidin-4-yl)pyridin-2-yl)oxy)naphthalen-1-yl)benzenesulfonamide, 2-Chloro-N-[6-methyl-5-[[3-[2-[(3S)-3-piperidinylamino]-4-pyrimidinyl]-2-pyridinyl]oxy]-1-naphthalenyl]benzenesulfonamide, AMG 18, AMG-18, AMG18, Compound 18, IRE1α Kinase-Inhibiting RNase Attenuator 8
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C31H29ClN6O3S
CAS Number:
Molecular Weight:
601.12
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
[S](=O)(=O)(Nc2c3c(c(c(cc3)C)Oc4ncccc4c5nc(ncc5)N[C@@H]6CNCCC6)ccc2)c1c(cccc1)Cl
InChI key
XMWUCMFVDXDRDE-NRFANRHFSA-N
Biochem/physiol Actions
ATP-competitive, potent and selective IRE1α kinase inhibitor that attenuates IRE1α endonuclease activity in vitro and in vivo.
KIRA8 is an ATP-competitive, potent and selective IRE1α kinase inhibitor (IRE1α/β Ki = 2/120 nM) that attenuates IRE1α endonuclease activity (IRE1α/β IC50 = 5/55 nM) with good kinome selectivity. KIRA8 inhibits thapsigargin-induced UPR (IC50 = 99 nM; HT1080 XBP1-Luc cells) and shows therapeutic efficacy in murine models of type 1 diabetes (T1D), pulmonary fibrosis, multiple myeloma (MM), and pancreatic neuroendocrine tumors (PanNET) in vivo (30-50 mg/kg/day i.p.).
Storage Class
11 - Combustible Solids
wgk
WGK 3
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2903-5MG | 04061842664559 |
| SML2903-25MG | 04061842664542 |